Seventy-nine patients with chronic lymphocytic leukaemia were evaluated for the presence of autoimmune diseases and autoantibodies. One patient has polymyositis and two additional patients presented with features suggestive of pernicious anaemia and chronic active hepatitis.
Introduction
Patients with chronic lymphocytic leukaemia (CLL) may develop features of autoimmunity. Coombs' positive haemolytic anaemia occurs in 15% to 35% of patients at some time during the course of the disease.' Autoimmune thrombocytopenia and neutropenia have been reported as well. 2'3 However, the occurrence of autoimmune diseases during the course of CLL is rare and only isolated cases have been reported hitherto. 4 We have evaluated, in a prospective study, whether there is an increased incidence of autoimmune diseases and autoantibodies in CLL patients.
Materials and methods
Seventy-nine B-type CLL patients followed in the Haematology Division, Beilinson Medical Center, from January 1975 to December 1984, were included in the study. The criterion for diagnosis of CLL was a sustained and absolute lymphocytosis of > 10 x lO9cells/litre in the peripheral blood To the best of our knowledge, prospective evaluation of the incidence of autoimmune disease in a large group of CLL patients has not been previously reported.
Seventy-nine patients with B-type CLL were included in the study group. Only one patient with definite autoimmune disease was identified. In this patient the diagnosis of connective tissue disease with polymyositis and CLL seems well established. In the second patient a diagnosis of pernicious anaemia was highly suggestive but a firm diagnosis was not reached. The third patient presented with clinical symptoms suggestive of chronic active hepatitis but a tissue diagnosis was not obtained. None of the other patients had any laboratory evidence suggestive of non-haematological autoimmune disease. The battery of blood tests that tested various immune functions did not yield any abnormal results.
The increased incidence of autoimmune haemolytic anaemia and autoimmune thrombocytopenia in CLL patients was confirmed also in our study group. Why they should develop these autoimmune disorders, particularly in the face of diminished Bcell function, is unknown. It is possible that the autoimmune process is caused by an imbalance of the T-cell subset. Disturbances of T-cells have been reported by many authors, with reduced numbers of T-helper cells and increased numbers of T-suppressor cells13 and concomitant changes in helper and suppressor function.'4 Abnormalities of macrophage function may be responsible for some of the immune abnormalities. 4 An additional interesting hypothesis is that previous therapy by irradiation or alkylating agents may trigger autoimmune complications in some of the patients. '5 In conclusion, we have demonstrated in our study that the propensity to develop autoantibodies is restricted to the haematopoietic system. No increased frequency of autoimmune diseases and autoantibodies was detected. Although connective tissue disease, with polymyositis and chronic active hepatitis have not been described in CLL so far we ascribe their occurrence here to a random association.
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